45 results
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
7 May 24
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
4:00pm
equivalents, and short-term investments as of March 31, 2024.
Research and development expenses were $4.9 million during the first quarter of 2024 … of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended March 31,
Operating expenses:
Research
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
28 Mar 24
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
4:00pm
.
Research and development (R&D) expenses were $17.6 million during the fourth quarter of 2023, compared to $10.4 million for the same period in 2022 … of $0.6 million in other research and development.
General and administrative (G&A) expenses were $7.4 million during the fourth quarter of 2023
424B5
4t86a
13 Nov 23
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
dmpp1m16g1w4srdgq3d
13 Nov 23
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:00pm
8-K
EX-99.1
76ppfgmek1q
10 Oct 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
h4wv5p ygo
10 Aug 23
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
x5092
11 May 23
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
4:07pm
424B5
9q9v0sgh350jdl 8hbi
4 May 23
Prospectus supplement for primary offering
5:15pm
424B5
yz3p1hx9ly1g3y4caln6
3 May 23
Prospectus supplement for primary offering
4:20pm